Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Neurology
Published in: Journal of Neurology 11/2015

01-11-2015 | Original Communication

Optical coherence tomography findings in Huntington’s disease: a potential biomarker of disease progression

Authors: Hannah M. Kersten, Helen V. Danesh-Meyer, Dean H. Kilfoyle, Richard H. Roxburgh

Published in: Journal of Neurology | Issue 11/2015

Login to get access

Abstract

Previous reports of ocular abnormalities in Huntington’s disease (HD) have detailed eye movement disorders. The objective of this case–control study was to investigate optic nerve and macular morphology in HD using optical coherence tomography (OCT). A total of 26 HD patients and 29 controls underwent a thorough ophthalmic examination including spectral domain OCT scans of the macula and peripapillary retinal nerve fibre layer (RNFL). Genetic testing results, disease duration, HD disease burden scores and Unified HD Rating Scale motor scores were acquired for HD patients. Temporal RNFL thickness was significantly reduced in the HD group (62.3 vs. 69.8 μm, p = 0.005), and there was a significant negative correlation between temporal RNFL thickness and disease duration (R 2 = −0.51, p = 0.04). Average peripapillary RNFL thickness was not significantly different between the HD and control groups. There was a significant negative correlation between macular volume and disease duration (R 2 = −0.71, p = 0.002), and motor scores (R 2 = −0.56, p = 0.01). Colour vision was significantly poorer in the HD group. Temporal RNFL is preferentially thinned in HD patients, possibly implicating mitochondrial dysfunction as the temporal RNFL is reduced in the patients with some mitochondrial disorders, including Leber’s hereditary optic neuropathy. The correlation between the decrease in macular volume and temporal RNFL, and increasing disease severity suggests that OCT may be a useful biomarker for disease progression in HD. Larger, longitudinal studies are required.
Literature
1.
Purdon SE, Mohr E, Ilivitsky V, Jones BD (1994) Huntington’s disease: pathogenesis, diagnosis and treatment. J Psychiatry Neurosci 19(5):359–367PubMedCentralPubMed
2.
Martin JB, Gusella JF (1986) Huntington’s disease. Pathogenesis and management. N Engl J Med 315(20):1267–1276CrossRefPubMed
3.
The Huntington’s Disease Collaborative Research Group and The Hungtinton Study Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s disease collaborative research group. Cell 72(6):971–83
4.
Stout JC, Paulsen JS, Queller S, Solomon AC, Whitlock KB, Campbell JC et al (2011) Neurocognitive signs in prodromal Huntington disease. Neuropsychology 25(1):1–14PubMedCentralCrossRefPubMed
5.
6.
Blekher T, Johnson SA, Marshall J, White K, Hui S, Weaver M et al (2006) Saccades in presymptomatic and early stages of Huntington disease. Neurology 67(3):394–399CrossRefPubMed
7.
Peltsch A, Hoffman A, Armstrong I, Pari G, Munoz DP (2008) Saccadic impairments in Huntington’s disease. Exp Brain Res 186(3):457–469CrossRefPubMed
8.
Lasker AG, Zee DS, Hain TC, Folstein SE, Singer HS (1988) Saccades in Huntington’s disease: slowing and dysmetria. Neurology 38(3):427–431CrossRefPubMed
9.
Leigh RJ, Newman SA, Folstein SE, Lasker AG, Jensen BA (1983) Abnormal ocular motor control in Huntington’s disease. Neurology 33(10):1268–1275CrossRefPubMed
10.
Anderson TJ, MacAskill MR (2013) Eye movements in patients with neurodegenerative disorders. Nat Rev Neurol 9(2):74–85CrossRefPubMed
11.
Sakai RE, Feller DJ, Galetta KM, Galetta SL, Balcer LJ (2011) Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol 31(4):362–373PubMedCentralCrossRefPubMed
12.
Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W et al (1991) Optical coherence tomography. Science 254(5035):1178–1181CrossRefPubMed
13.
Wojtkowski M, Srinivasan VJ, Ko TH, Fujimoto JG, Kowalczyk A, Duker JS (2004) Ultrahigh-resolution, high-speed, Fourier domain optical coherence tomography and methods for dispersion compensation. Opt Express 12(11):2404–2422CrossRefPubMed
14.
Altintas O, Iseri P, Ozkan B, Caglar Y (2008) Correlation between retinal morphological and functional findings and clinical severity in Parkinson’s disease. Doc Ophthalmol 116(2):137–146CrossRefPubMed
15.
Fisher JB, Jacobs DA, Markowitz CE, Galetta SL, Volpe NJ, Nano-Schiavi ML et al (2006) Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 113(2):324–332CrossRefPubMed
16.
Gordon-Lipkin E, Chodkowski B, Reich DS, Smith SA, Pulicken M, Balcer LJ et al (2007) Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 69(16):1603–1609CrossRefPubMed
17.
18.
Iseri PK, Altinas O, Tokay T, Yuksel N (2006) Relationship between cognitive impairment and retinal morphological and visual functional abnormalities in Alzheimer disease. J Neuroophthalmol 26(1):18–24CrossRefPubMed
19.
Klistorner A, Garrick R, Barnett MH, Graham SL, Arvind H, Sriram P et al (2013) Axonal loss in nonoptic neuritis eyes of patients with multiple sclerosis linked to delayed visual evoked potential. Neurology 80(3):242–245CrossRefPubMed
20.
Lange AP, Sadjadi R, Zhu F, Alkabie S, Costello F, Traboulsee AL (2013) Spectral-domain optical coherence tomography of retinal nerve fiber layer thickness in NMO patients. J Neuroophthalmol 33(3):213–219CrossRefPubMed
21.
Llufriu S, Sepulveda M, Blanco Y, Marin P, Moreno B, Berenguer J et al (2014) Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis. Plos One 9(12):e113936PubMedCentralCrossRefPubMed
22.
Merle H, Olindo S, Donnio A, Richer R, Smadja D, Cabre P (2008) Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest Ophthalmol Vis Sci 49(10):4412–4417CrossRefPubMed
23.
Polo V, Garcia-Martin E, Bambo MP, Pinilla J, Larrosa JM, Satue M et al (2014) Reliability and validity of Cirrus and Spectralis optical coherence tomography for detecting retinal atrophy in Alzheimer’s disease. Eye (Basingstoke) 28(6):680–690
24.
Satue M, Garcia-Martin E, Fuertes I, Otin S, Alarcia R, Herrero R et al (2013) Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson’s disease patients. Eye 27(4):507–514PubMedCentralCrossRefPubMed
25.
Galetta KM, Calabresi PA, Frohman EM, Balcer LJ (2011) Optical coherence tomography (OCT): imaging the visual pathway as a model for neurodegeneration. Neurotherapeutics 8(1):117–132PubMedCentralCrossRefPubMed
26.
Reilmann R, Bohlen S, Kirsten F, Ringelstein EB, Lange HW (2011) Assessment of involuntary choreatic movements in Huntington’s disease–toward objective and quantitative measures. Mov Disord 26(12):2267–2273CrossRefPubMed
27.
Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH (1997) CAG repeat number governs the development rate of pathology in Huntington’s disease. Ann Neurol 41(5):689–692CrossRefPubMed
28.
Kersten HM, Roxburgh RH, Danesh-Meyer HV (2014) Ophthalmic manifestations of inherited neurodegenerative disorders. Nat Rev Neurol 10(6):349–362CrossRefPubMed
29.
Fortuna F, Barboni P, Liguori R, Valentino ML, Savini G, Gellera C et al (2009) Visual system involvement in patients with Friedreich’s ataxia. Brain 132(Pt 1):116–123PubMed
30.
Sitarz KS, Chinnery PF, Yu-Wai-Man P (2012) Disorders of the optic nerve in mitochondrial cytopathies: new ideas on pathogenesis and therapeutic targets. Curr Neurol Neurosci Rep 12(3):308–317PubMedCentralCrossRefPubMed
31.
Barboni P, Savini G, Valentino ML, Montagna P, Cortelli P, De Negri AM et al (2005) Retinal nerve fiber layer evaluation by optical coherence tomography in Leber’s hereditary optic neuropathy. Ophthalmology 112(1):120–126CrossRefPubMed
32.
Klebe S, Depienne C, Gerber S, Challe G, Anheim M, Charles P et al (2012) Spastic paraplegia gene 7 in patients with spasticity and/or optic neuropathy. Brain 135(Pt 10):2980–2993PubMedCentralCrossRefPubMed
33.
34.
Sadun AA, Win PH, Ross-Cisneros FN, Walker SO, Carelli V (2000) Leber’s hereditary optic neuropathy differentially affects smaller axons in the optic nerve. Trans Am Ophthalmol Soc 98:223–232PubMedCentralPubMed
35.
Zuccato C, Valenza M, Cattaneo E (2010) Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol Rev 90(3):905–981CrossRefPubMed
36.
Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA et al (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington’s disease: implications for selective neuronal damage. Hum Mol Genet 20(7):1438–1455PubMedCentralCrossRefPubMed
37.
Orr AL, Li S, Wang CE, Li H, Wang J, Rong J et al (2008) N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28(11):2783–2792PubMedCentralCrossRefPubMed
38.
39.
Helmlinger D, Yvert G, Picaud S, Merienne K, Sahel J, Mandel J-L et al (2002) Progressive retinal degeneration and dysfunction in R6 Huntington’s disease mice. Hum Mol Genet 11(26):3351–3359CrossRefPubMed
40.
Paulus W, Schwarz G, Werner A, Lange H, Bayer A, Hofschuster M et al (1993) Impairment of retinal increment thresholds in Huntington’s disease. Ann Neurol 34(4):574–578CrossRefPubMed
41.
Petrasch-Parwez E, Saft C, Schlichting A, Andrich J, Napirei M, Arning L et al (2005) Is the retina affected in Huntington disease? Acta Neuropathol 110(5):523–525CrossRefPubMed
42.
Petrasch-Parwez E, Habbes H-W, Weickert S, Lobbecke-Schumacher M, Striedinger K, Wieczorek S et al (2004) Fine-structural analysis and connexin expression in the retina of a transgenic model of Huntington’s disease. J Comp Neurol 479(2):181–197CrossRefPubMed
43.
Batcha AH, Greferath U, Jobling AI, Vessey KA, Ward MM, Nithianantharajah J et al (2012) Retinal dysfunction, photoreceptor protein dysregulation and neuronal remodelling in the R6/1 mouse model of Huntington’s disease. Neurobiol Dis 45(3):887–896CrossRefPubMed
44.
Li M, Yasumura D, Ma AAK, Matthes MT, Yang H, Nielson G et al (2013) Intravitreal administration of HA-1077, a ROCK inhibitor, improves retinal function in a mouse model of huntington disease. Plos One 8(2):e56026PubMedCentralCrossRefPubMed
45.
Ragauskas S, Leinonen H, Puranen J, Ronkko S, Nymark S, Gurevicius K et al (2014) Early retinal function deficit without prominent morphological changes in the R6/2 mouse model of Huntington’s disease. Plos One 9(12):e113317PubMedCentralCrossRefPubMed
46.
Mizuno K, Asaoka M (1976) Cycloscopy and fluorescein cycloscopy. Investig Ophthalmol 15(7):561–564
47.
Dorsey ER, Beck CA, Darwin K, Nichols P, Brocht AFD, Biglan KM et al (2013) Natural history of Huntington disease. JAMA Neurol 70(12):1520–1530PubMed
48.
The Huntington’s Disease Collaborative Research Group and The Hungtinton Study Group (1996) Unified Huntington’s disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord 11(2):136–42
49.
Stroet A, Linker RA, Gold R (2013) Advancing therapeutic options in multiple sclerosis with neuroprotective properties. J Neural Transm 120(Suppl 1):S49–S53CrossRefPubMed
Metadata
Title
Optical coherence tomography findings in Huntington’s disease: a potential biomarker of disease progression
Authors
Hannah M. Kersten
Helen V. Danesh-Meyer
Dean H. Kilfoyle
Richard H. Roxburgh
Publication date
01-11-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 11/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7869-2

Other articles of this Issue 11/2015

Journal of Neurology 11/2015 Go to the issue

Original Communication

Analysis and meta-analysis of five polymorphisms of the LINGO1 and LINGO2 genes in Parkinson’s disease and multiple system atrophy in a Chinese population

Neurological Update

Deep brain stimulation for movement disorders: update on recent discoveries and outlook on future developments

Short Commentary

Glucocorticoids improve acute dizziness symptoms following acute unilateral vestibulopathy

Original Communication

Predictors of disease activity in 857 patients with MS treated with interferon beta-1b

Original Communication

Fall risk is associated with amplified functional connectivity of the central executive network in patients with Parkinson’s disease

Original Communication

C9ORF72 intermediate repeat expansion in patients affected by atypical parkinsonian syndromes or Parkinson’s disease complicated by psychosis or dementia in a Sardinian population